Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ab&B Bio-Tech Partners with Walvax for Overseas Push – First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets

Fineline Cube Mar 16, 2026
Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Policy / Regulatory

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

Fineline Cube Mar 16, 2026
Company Drug

CMS Secures NMPA Approval for Desidustat – First Domestic HIF-PHI for Non-Dialysis CKD Anemia Enters China Market

Fineline Cube Mar 16, 2026
Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Fineline Cube Mar 16, 2026
Company Deals

SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal

Fineline Cube Jan 13, 2026

SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE: NVS) to advance its next‑generation amyloid...

Company Deals

CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR‑T in Solid Tumors

Fineline Cube Jan 13, 2026

CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP‑11,...

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026

Noetik, an AI‑native biotech pioneering self‑supervised machine learning in cancer therapeutics, announced a five‑year strategic...

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026

Alphamab Oncology (HKG: 9966) announced that China’s National Medical Products Administration (NMPA) has accepted its marketing...

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026

Pfizer Inc. (NYSE: PFE) announced that Cohort 3 of the pivotal Phase 3 BREAKWATER trial met its primary...

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Fineline Cube Jan 12, 2026

Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA...

Company Drug

Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response

Fineline Cube Jan 12, 2026

Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a pivotal Phase III trial of zemprocitinib...

Company Medical Device

Lifetech Scientific Secures NMPA Approval for G‑iliac Pro – Upgraded Iliac Branch Device for Aortic Aneurysm Repair

Fineline Cube Jan 12, 2026

Lifetech Scientific Corporation (HKG: 1302) announced that China’s National Medical Products Administration (NMPA) has granted market...

Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026

Mirxes Holding Company Ltd, a Singapore‑headquartered RNA technology company, announced a strategic partnership with N...

Company Drug

Santen’s UPNEEQ Wins Japan Approval for Acquired Ptosis

Fineline Cube Jan 12, 2026

Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved...

Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced an option and license agreement...

Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026

Simcere Pharmaceutical Group Limited (HKG: 2096) announced plans to spin off its subsidiary Simcere Zaiming...

Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026

Nona Biosciences, a wholly‑owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi‑target antibody...

Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Fineline Cube Jan 12, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that the National Medical Products...

Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Fineline Cube Jan 12, 2026

Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical...

Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026

The FDA’s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle‑based approach to...

Company Drug

Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia

Fineline Cube Jan 12, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long‑acting triple‑target agonist developed by...

Medical Device

Dongcheng Pharma’s PSMA PET Agent [18F] Spiritide NDA Accepted by NMPA

Fineline Cube Jan 12, 2026

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced that the New Drug Application (NDA)...

Company

Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity

Fineline Cube Jan 12, 2026

Novartis AG (NYSE: NVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in...

Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Fineline Cube Jan 12, 2026

Pierre Fabre Laboratories announced a comprehensive drug discovery collaboration with French AI specialist Iktos to...

Posts pagination

1 … 27 28 29 … 635

Recent updates

  • Ab&B Bio-Tech Partners with Walvax for Overseas Push – First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets
  • CMS Secures NMPA Approval for Desidustat – First Domestic HIF-PHI for Non-Dialysis CKD Anemia Enters China Market
  • Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine
  • 3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market
  • Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Ab&B Bio-Tech Partners with Walvax for Overseas Push – First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets

Company Drug

CMS Secures NMPA Approval for Desidustat – First Domestic HIF-PHI for Non-Dialysis CKD Anemia Enters China Market

Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.